In:
Chinese Journal of Chemistry, Wiley, Vol. 31, No. 9 ( 2013-09), p. 1199-1206
Abstract:
SARS CoV 3CL pro is known to be a promising target for development of therapeutic agents against the severe acute respiratory syndrome (SARS). A quinolinone compound 1 was selected via virtual screening, and it was synthetized and tested for enzymatic inhibition in vitro . Compound 1 showed potent inhibitory activity (IC 50 =0.44 µmol/L) toward SARS CoV 3CL pro . Further work on a series of quinolinone derivatives resulted in the discovery of the most potent compound 23 , inhibiting SARS CoV 3CL pro with an IC 50 of 36.86 nmol/L. The structure‐activity relationships were also discussed.
Type of Medium:
Online Resource
ISSN:
1001-604X
,
1614-7065
DOI:
10.1002/cjoc.201300392
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2144352-X
SSG:
6,25
Permalink